Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer

Heeman Kim, Seungmin Bang, Jeong Youp Park, Jinsil Seong, Si Young Song, Jae Bock Chung, Seung Woo Park

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Purpose: S-1 has a favorable effect in unresectable pancreatic cancer and a potential radiosensitizer. In addition, daily oral administration of S-1 is more convenient than continuous infusion of 5-fluorouracil. This study was designed to evaluate the efficacy and safety of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Methods: Eligibility criteria were histologically proven pancreatic adenocarcinoma, locally advanced disease, and no previous treatment. S-1 was administered orally at a dose of 40 mg/m2 twice daily from day 1 to 14 and from day 22 to 35, and concurrent radiotherapy (a total dose of 50.4 Gy) was delivered in 28 fractions. One month after treatment completion, tumor response was evaluated by computed tomography (CT). Results: A total of 25 patients were evaluable for efficacy and toxicity on the basis of the intention-to-treat analysis. The response rate and disease control rate were 24.0 and 68.0%, respectively. There was no treatment-related death or grade 4 toxicity. The most common grade 3 hematologic and non-hematologic toxicities were thrombocytopenia (4.0%) and anorexia (20%), respectively. All toxicities were tolerable and transient. The median time-to-progression and median overall survival were 6.5 months (95% confidence interval, 4.1-9.0 months) and 12.9 months (95% confidence interval, 6.7-19.0 months), respectively, and the 1-year survival rate was estimated to be 43%. Conclusions: S-1 and concurrent radiotherapy shows favorable efficacy for disease control against locally advanced pancreatic cancer and was well tolerated with no severe toxicities.

Original languageEnglish
Pages (from-to)535-541
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Volume63
Issue number3
DOIs
Publication statusPublished - 2009 Feb 1

Fingerprint

Radiotherapy
Pancreatic Neoplasms
Toxicity
Disease control
Confidence Intervals
Intention to Treat Analysis
Anorexia
Fluorouracil
Thrombocytopenia
Oral Administration
Adenocarcinoma
Therapeutics
Survival Rate
Tomography
Safety
Survival
Dosimetry
Tumors
Neoplasms

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

Kim, Heeman ; Bang, Seungmin ; Park, Jeong Youp ; Seong, Jinsil ; Song, Si Young ; Chung, Jae Bock ; Park, Seung Woo. / Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer. In: Cancer Chemotherapy and Pharmacology. 2009 ; Vol. 63, No. 3. pp. 535-541.
@article{7b38d4bef07b4f0695a4e059ee5090f2,
title = "Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer",
abstract = "Purpose: S-1 has a favorable effect in unresectable pancreatic cancer and a potential radiosensitizer. In addition, daily oral administration of S-1 is more convenient than continuous infusion of 5-fluorouracil. This study was designed to evaluate the efficacy and safety of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Methods: Eligibility criteria were histologically proven pancreatic adenocarcinoma, locally advanced disease, and no previous treatment. S-1 was administered orally at a dose of 40 mg/m2 twice daily from day 1 to 14 and from day 22 to 35, and concurrent radiotherapy (a total dose of 50.4 Gy) was delivered in 28 fractions. One month after treatment completion, tumor response was evaluated by computed tomography (CT). Results: A total of 25 patients were evaluable for efficacy and toxicity on the basis of the intention-to-treat analysis. The response rate and disease control rate were 24.0 and 68.0{\%}, respectively. There was no treatment-related death or grade 4 toxicity. The most common grade 3 hematologic and non-hematologic toxicities were thrombocytopenia (4.0{\%}) and anorexia (20{\%}), respectively. All toxicities were tolerable and transient. The median time-to-progression and median overall survival were 6.5 months (95{\%} confidence interval, 4.1-9.0 months) and 12.9 months (95{\%} confidence interval, 6.7-19.0 months), respectively, and the 1-year survival rate was estimated to be 43{\%}. Conclusions: S-1 and concurrent radiotherapy shows favorable efficacy for disease control against locally advanced pancreatic cancer and was well tolerated with no severe toxicities.",
author = "Heeman Kim and Seungmin Bang and Park, {Jeong Youp} and Jinsil Seong and Song, {Si Young} and Chung, {Jae Bock} and Park, {Seung Woo}",
year = "2009",
month = "2",
day = "1",
doi = "10.1007/s00280-008-0836-1",
language = "English",
volume = "63",
pages = "535--541",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer. / Kim, Heeman; Bang, Seungmin; Park, Jeong Youp; Seong, Jinsil; Song, Si Young; Chung, Jae Bock; Park, Seung Woo.

In: Cancer Chemotherapy and Pharmacology, Vol. 63, No. 3, 01.02.2009, p. 535-541.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer

AU - Kim, Heeman

AU - Bang, Seungmin

AU - Park, Jeong Youp

AU - Seong, Jinsil

AU - Song, Si Young

AU - Chung, Jae Bock

AU - Park, Seung Woo

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Purpose: S-1 has a favorable effect in unresectable pancreatic cancer and a potential radiosensitizer. In addition, daily oral administration of S-1 is more convenient than continuous infusion of 5-fluorouracil. This study was designed to evaluate the efficacy and safety of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Methods: Eligibility criteria were histologically proven pancreatic adenocarcinoma, locally advanced disease, and no previous treatment. S-1 was administered orally at a dose of 40 mg/m2 twice daily from day 1 to 14 and from day 22 to 35, and concurrent radiotherapy (a total dose of 50.4 Gy) was delivered in 28 fractions. One month after treatment completion, tumor response was evaluated by computed tomography (CT). Results: A total of 25 patients were evaluable for efficacy and toxicity on the basis of the intention-to-treat analysis. The response rate and disease control rate were 24.0 and 68.0%, respectively. There was no treatment-related death or grade 4 toxicity. The most common grade 3 hematologic and non-hematologic toxicities were thrombocytopenia (4.0%) and anorexia (20%), respectively. All toxicities were tolerable and transient. The median time-to-progression and median overall survival were 6.5 months (95% confidence interval, 4.1-9.0 months) and 12.9 months (95% confidence interval, 6.7-19.0 months), respectively, and the 1-year survival rate was estimated to be 43%. Conclusions: S-1 and concurrent radiotherapy shows favorable efficacy for disease control against locally advanced pancreatic cancer and was well tolerated with no severe toxicities.

AB - Purpose: S-1 has a favorable effect in unresectable pancreatic cancer and a potential radiosensitizer. In addition, daily oral administration of S-1 is more convenient than continuous infusion of 5-fluorouracil. This study was designed to evaluate the efficacy and safety of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Methods: Eligibility criteria were histologically proven pancreatic adenocarcinoma, locally advanced disease, and no previous treatment. S-1 was administered orally at a dose of 40 mg/m2 twice daily from day 1 to 14 and from day 22 to 35, and concurrent radiotherapy (a total dose of 50.4 Gy) was delivered in 28 fractions. One month after treatment completion, tumor response was evaluated by computed tomography (CT). Results: A total of 25 patients were evaluable for efficacy and toxicity on the basis of the intention-to-treat analysis. The response rate and disease control rate were 24.0 and 68.0%, respectively. There was no treatment-related death or grade 4 toxicity. The most common grade 3 hematologic and non-hematologic toxicities were thrombocytopenia (4.0%) and anorexia (20%), respectively. All toxicities were tolerable and transient. The median time-to-progression and median overall survival were 6.5 months (95% confidence interval, 4.1-9.0 months) and 12.9 months (95% confidence interval, 6.7-19.0 months), respectively, and the 1-year survival rate was estimated to be 43%. Conclusions: S-1 and concurrent radiotherapy shows favorable efficacy for disease control against locally advanced pancreatic cancer and was well tolerated with no severe toxicities.

UR - http://www.scopus.com/inward/record.url?scp=58249132914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58249132914&partnerID=8YFLogxK

U2 - 10.1007/s00280-008-0836-1

DO - 10.1007/s00280-008-0836-1

M3 - Article

C2 - 18828020

AN - SCOPUS:58249132914

VL - 63

SP - 535

EP - 541

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -